

RFB4 LIGHT CHAIN

1	D	I	Q	M	T	Q	T	S	L	S	A	S	L	G	D	R	V	T	
1	gat	atc	cag	atg	acc	cag	act	aca	tcc	tcc	gtc	tct	gcc	tct	ctg	ggc	aga	gtc	acc
21	I	S	C	R	A	S	Q	D	I	S	N	Y	L	N	W	Y	Q	K	P
61	att	agt	tgc	agg	gca	agt	cag	gac	att	agc	aat	tat	tta	aat	tat	tgg	tat	cag	cag
41	D	G	T	V	K	L	L	I	Y	Y	T	S	I	L	H	S	G	V	P
121	gat	gga	act	gtt	aaa	ctc	ctg	atc	tac	tac	aca	tca	ata	tta	cac	tca	ggg	gtc	cca
61	R	F	S	G	S	G	T	'D	Y	S	L	T	I	S	N	L	E	Q	
181	agg	ttc	agt	ggc	agt	ggg	tct	gga	aca	gat	tat	tct	ctc	acc	att	agc	aac	ctg	gag
81	E	D	F	A	T	Y	F	C	Q	Q	G	N	T	L	P	W	T	F	G
241	gaa	gat	ttt	gcc	act	tac	ttt	tgc	caa	cag	ggt	aat	acg	ctt	ccg	tgg	acg	ttc	ggg
101	G	T	K	L	E	I	K	107											
301	ggc	acc	aag	ctg	gaa	atc	aaa	121											

RFB4 HEAVY CHAIN

1	E	V	Q	L	V	E	S	G	G	G	L	V	K	P	G	G	S	L	K	L	
1	gaa	gtg	cag	ctg	gtg	gtg	gag	tct	ggg	ggg	ggc	tta	gtg	aag	cct	ggg	ggg	tcc	ctg	aaa	ctc
21	S	C	A	A	S	G	F	A	F	S	I	Y	D	M	S	W	V	R	Q	T	
61	tcc	tgt	gca	gcc	tct	ggg	tcc	gct	tcc	agt	atc	tat	gac	atg	tct	tgg	gtt	cgc	cag	act	120
41	P	E	K	R	L	E	W	V	A	Y	I	S	S	G	G	T	T	Y	Y	60	
121	ccg	gag	aag	agg	ctg	gag	tgg	gtc	gca	tac	att	agt	agt	ggt	ggt	acc	acc	tac	tat	180	
61	P	D	T	V	K	G	R	F	T	I	S	R	D	N	A	K	N	T	L	Y	
181	cca	gac	act	gtg	aag	ggc	cga	tcc	acc	atc	tcc	aga	gac	aat	gcc	aag	aac	acc	ctg	tac	240
81	L	Q	M	S	S	L	K	S	E	D	T	A	M	Y	Y	C	A	R	H	S	
241	ctg	caa	atg	agg	agt	ctg	aag	tct	gag	gac	aca	gcc	atg	tat	tac	tgt	gca	aga	cat	agt	300
101	G	Y	G	S	S	Y	G	V	L	F	A	Y	W	G	Q	G	T	L	V	T	
301	ggc	tac	ggt	agt	agg	tac	ggg	gtt	tgg	tcc	gct	tac	tgg	ggc	caa	ggg	act	ctg	gtc	act	360
121	T	S	A	123																	
361	gtc	tct	gca	369																	

Figure 1

Figure ZA




Figure 2B




Fig 3






Fig 5




6/10

Fig 5




7/10

6 A




6 B




8/10

7 A



7B



9/10

ANTITUMOR ACTIVITY OF RFB4(dsFv)-PE38 IN MICE




Figure 8A

Figure 8B

PHARMACOKINETICS OF RFB4(dsFv)-PE38




Figure 9A




Figure 9B